



MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

MCL/SE/2025-2026

Date: 11.02.2026

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers, 'A' wing
Dalal Street Fort, Mumbai – 400001 (M.H.)

SUBJECT: OUTCOME OF BOARD MEETING HELD ON 11TH FEBRUARY, 2026
PURSUANT TO REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND
DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board of Directors at their meeting held on today i.e. Wednesday 11th February, 2026 has inter alia considered and approved the following businesses:

- (1) Un-audited Standalone and Consolidated Financial Results of the Company for the quarter as well as nine months ended on 31st December, 2025 along with the Limited Review Report thereon.
- (2) Other routine businesses with the permission of chair.

Further, a copy of aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be submitted in XBRL mode (Integrated Filing Financial) within prescribed time limit.

The aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be uploaded on the Company's website www.medicaps.com and on the website of the Stock Exchange at www.bseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit.

The Meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 03:50 P.M.



MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

The above information will also be available on the website of the Company at www.medicaps.com.

This is for your information and record.

Thanking You,

Yours Faithfully,

FOR MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321


Encl.: Un-audited Standalone and Consolidated Financial Results along with limited review report for quarter as well as nine months ended on 31st December, 2025.

LIMITED REVIEW REPORT**Independent Auditor's Review Report on Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2025 of Medi-Caps Limited (the Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.**

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED
INDORE

SCOPE OF THE REVIEW

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter and nine months ended 31st December 2025 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



CONCLUSION

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 11/02/2026

Place: Indore

UDIN: 26429040CRIRGR2770

For, Rawka & Associates


(Chartered Accountants)

FRN 021606C

 Venus Rawka

(Partner)

M. No. 429040



MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31.12.2025

(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended		Nine Month Ended		Year Ended
		Dec 31st, 2025	Sept 30th, 2025	Dec 31st, 2024	Dec 31st, 2025	Mar 31st, 2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operation					
	(a) Net sales	77.28	99.78	25.28	177.06	149.04
	(b) Other operating income	0.00	0.18	0.76	0.18	3.54
	Revenue from Operation	77.28	99.96	26.04	177.24	152.58
II	Other Income	17.32	0.97	8.96	49.62	29.34
III	Total income (I+II)	94.60	100.93	35.00	226.86	181.92
IV	Expenses					
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.10	0.15	0.06	0.25	0.28
	d) Employee benefits expense	46.73	45.90	45.52	138.29	136.14
	e) Finance costs	0.00	0.00	0.00	0.00	0.00
	f) Depreciation and amortisation expense	4.00	4.00	4.00	12.01	12.01
	g) Power Cost	2.30	0.37	0.07	3.24	0.22
	h) Freight Exp.	0.00	0.00	0.00	0.00	0.00
	i) Other expenses	10.12	21.86	11.82	52.80	48.37
	Total Expenses (IV)	63.25	72.28	61.47	206.59	197.02
V	Profit/(Loss) before exceptional item & tax (III-IV)	31.35	28.65	-26.47	20.27	-15.10
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII	Profit/(Loss) before tax (V-VI)	31.35	28.65	-26.47	20.27	-15.10
VIII	Tax expense					
	1) Current Tax	0.00	0.00	0.00	0.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	2.85	0.00	0.00	2.85	0.00
	3) Deferred Tax	0.00	0.00	0.00	0.00	-1.45
	Total Tax Expenses	2.85	0.00	0.00	2.85	0.00
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00
X	Profit (Loss) for the period from continuing operations (VII-VIII)	28.50	28.65	-26.47	17.42	-15.10
XI	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	0.00	0.00	0.00	0.00	0.00
XIV	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00
XV	Profit/(loss) for the period (X+XIII)	28.50	28.65	-26.47	17.42	-15.10
XVI	Other comprehensive income					
	(a) (i) items that will not be reclassified to statement of profit & loss	22.62	-11.83	-38.46	65.04	55.32
	(ii) Income tax on items that will not be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00
	Other comprehensive income :	22.62	-11.83	-38.46	65.04	55.32
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	51.12	16.82	-64.93	82.46	40.22
XVIII	Profit or Loss Attributable to					
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to					
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00

XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	0.00	0.00	5487.39
XXII	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	0.23	0.23	-0.21	0.14	-0.12	0.45
	b) Diluted (Rs.)	0.23	0.23	-0.21	0.14	-0.12	0.45
XXIII	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	0.23	0.23	-0.21	0.14	-0.12	0.45
	b) Diluted (Rs.)	0.23	0.23	-0.21	0.14	-0.12	0.45

DATE: 11.02.2026

PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED


ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321


LIMITED REVIEW REPORT

Independent Auditor's Review Report on Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended 31st December, 2025 of Medi-Caps Limited (the Parent Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED
INDORE-MP

SCOPE OF THE REVIEW

1. We have reviewed the accompanying Statement of the Consolidated Un-audited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent Company") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter and nine months ended December 31, 2025, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the SEBI Listing Regulations'), including relevant circular issued by the SEBI time to time.
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Schedule 10 of the Companies Act, 2013 and



consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly owned subsidiary **Medgel Private Limited**.

CONCLUSION

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Parent Company's Management, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI- (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the financial results of Medgel Private Limited (wholly owned subsidiary) which also has been reviewed by us and certified by the management, whose nine months consolidated financial results reflect a total income of Rs. 935.26 Lakhs, total net Profit/loss after tax of Rs.-625.35 Lakhs and total comprehensive income of Rs. -400.51 /- Lakhs for the quarter ended December, 31st 2025 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of the above matter.

Date: 11/02/2026

Place: Indore

UDIN: 26429040AXTBM2227

For, Rawka & Associates

(Chartered Accountants)

FRN 021606C



Venus Rawka

(Partner)

M. No. 429040

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31.12.2025

(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		Dec 31st, 2025	Sept 30th, 2025	Dec 31st, 2024	Dec 31st, 2025	Dec 31st, 2024	Mar 31st, 2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operation						
	(a) Net sales	429.21	200.53	400.91	897.40	1843.93	2537.44
	(b) Other operating income	0.73	0.67	1.39	2.51	7.43	10.27
	Revenue from Operation	429.94	201.20	402.30	899.91	1851.36	2547.71
II	Other Income	75.89	152.83	15.90	262.21	59.11	272.95
III	Total income (I+II)	505.83	354.03	418.20	1162.12	1910.47	2820.66
IV	Expenses						
	a) Cost of material consumed	128.58	128.00	138.78	425.78	744.73	1016.99
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	61.54	-66.90	49.38	-15.71	42.81	48.17
	d) Employee benefits expense	186.17	185.26	178.53	557.49	538.18	758.36
	e) Finance costs	0.00	0.00	0.00	1.30	0.00	2.48
	f) Depreciation and amortisation expense	43.68	43.68	42.57	131.04	127.70	171.82
	g) Power Cost	53.16	36.48	31.69	143.11	126.62	167.72
	h) Freight Exp.	18.65	27.88	15.99	86.23	117.03	137.14
	i) Other expenses	87.78	181.78	165.76	437.96	442.32	602.09
	Total Expenses (IV)	579.56	536.18	622.70	1767.20	2139.39	2904.77
V	Profit/(Loss) before exceptional item & tax (III-IV)	-73.73	-182.15	-204.50	-605.08	-228.92	-84.11
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V-VI)	-73.73	-182.15	-204.50	-605.08	-228.92	-84.11
VIII	Tax expense						
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	2.85	0.00	0.00	2.85	0.00	-25.56
	3) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-1.45
	Total Tax Expenses	2.85	0.00	0.00	2.85	0.00	-27.01
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
X	Profit (Loss) for the period from continuing operations (VII-VIII)	-76.58	-182.15	-204.50	-607.93	-228.92	-57.10
XI	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	0.00	0.00	0.00	0.00	0.00	0.00
XIV	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
XV	Profit/(loss) for the period (X+XII)	-76.58	-182.15	-204.50	-607.93	-228.92	-57.10
XVI	Other comprehensive income						
	(a) (i) items that will not be reclassified to statement of profit & loss	60.14	-87.61	-52.61	124.96	246.02	86.43
	(ii) Income tax on items that will not be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00	0.00
	Other comprehensive income :	60.14	-87.61	-52.61	124.96	246.02	86.43
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	-16.44	-269.76	-257.11	-482.97	17.10	29.33
XVIII	Profit or Loss Attributable to						
	Profit or Loss Attributable to owners of Parents	-76.58	-182.15	-204.50	-607.93	-228.92	-57.10
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to						
	Total Comprehensive Income for the period Attributable to owners of Parents	-16.44	-269.76	-257.11	-482.97	17.10	29.33
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00

XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	0.00	0.00	10880.66
XXII	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	-0.61	-1.46	-1.64	-4.88	-1.84	-0.46
	b) Diluted (Rs.)	-0.61	-1.46	-1.64	-4.88	-1.84	-0.46
XXIII	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	-0.61	-1.46	-1.64	-4.88	-1.84	-0.46
	b) Diluted (Rs.)	-0.61	-1.46	-1.64	-4.88	-1.84	-0.46

DATE: 11.02.2026

PLACE: INDORE

**For and on behalf of board of directors of
MEDI-CAPS LIMITED**



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

UNAUDITED CONSOLIDATED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE QUARTER AND NINE MONTH ENDED 31.12.2025

S.No.	Segment Revenue	Quarter Ended			Nine Month Ended		(Amount in Lacs)
		Dec 31st, 2025	Sept 30th, 2025	Dec 31st, 2024	Dec 31st, 2025	Dec 31st, 2024	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	Pharma Division	352.66	101.24	376.26	722.67	1698.78	2306.05
	Real Estate Division	77.28	99.96	26.04	177.24	152.58	241.66
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Net Sale/Income From Operations	429.94	201.20	402.30	899.91	1851.36	2547.71
2	Segment Results (Profit) (+)/ Loss (-) before tax and Interest						
	Pharma Division	-105.08	-210.80	-178.03	-624.05	-213.82	-110.13
	Real Estate Division	31.35	28.65	-26.47	20.27	-15.10	28.50
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total	-73.73	-182.15	-204.50	-603.78	-228.92	-81.63
	Interest Income	0.00	0.00	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	0.00	0.00	1.30	0.00	2.48
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00	0.00	0.00
	Profit Before Tax	-73.73	-182.15	-204.50	-605.08	-228.92	-84.11
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	5147.61	5297.33	5881.60	5147.61	5881.60	5739.66
	Real Estate Division	6875.10	6828.93	6751.70	6875.10	6751.70	6802.66
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (A)	12022.71	12126.26	12633.30	12022.71	12633.30	12542.32
	Segment Liabilities (B)						
	Pharma Division	319.77	401.90	455.32	319.77	455.32	346.40
	Real Estate Division	58.24	63.20	62.56	58.24	62.56	68.27
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (B)	378.01	465.10	517.88	378.01	517.88	414.67
4	Total Capital Employed (Segment Assets-Segment Liabilities)						
	Pharma Division	4827.84	4895.43	5426.27	4827.84	5426.27	5393.27
	Real Estate Division	6816.86	6765.73	6689.15	6816.86	6689.15	6734.39
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	11644.70	11661.16	12115.42	11644.70	12115.42	12127.66

DATE: 11.02.2026

PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

Alok K Garg
MANAGING DIRECTOR
DIN: 00274321


NOTES:

1. The above standalone and consolidated unaudited financial results for the Quarter and Nine months ended December 31, 2025, were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on February 11, 2026. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised the necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. This statement has been prepared in accordance with the guidelines issued by the Securities Exchange Board of India (SEBI) and Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated results included the result of wholly owned subsidiary company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists of Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
5. During this quarter the Company has generated revenue of Rs. 77.28 Lacs from sale of shops at Medi-caps Business Park.
6. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.
7. The aforesaid unaudited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available, will be published in English and Hindi Newspapers within prescribed time limit.

DATE:11/02/2026

PLACE: INDORE

**For and on behalf of the Board of directors of
MEDI-CAPS LIMITED**


ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321